-+ 0.00%
-+ 0.00%
-+ 0.00%

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Benzinga·12/05/2024 16:37:31
Listen to the news
Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $15 price target.